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Transcatheter aortic valve replacement (TAVR) has become the
therapeutic option of choice for patients with symptomatic, severe
aortic valve stenosis (AS) who are at increased risk for surgical aortic
valve replacement (SAVR) [1]. During the last decade, technological
improvements in transcatheter heart valves (THVs) have led to a sig-
nificant increase in TAVR safety and efficacy. The results from recent
randomized controlled trials (RCTs) and large registries have expanded
the indication for TAVR to lower risk patients as an alternative to SAVR
[2–5]. Although the above-mentioned TAVR studies included patients
with a lower surgical risk, the mean age of enrolled patients was not
different compared to the early TAVR trials conducted in extreme or
high risk patients. When considering further expansion of TAVR indica-
tions to encompass younger patients aged 75 years or less, there are still
some challenges ahead. This review aims to summarize the evidence
supporting the expansion of TAVR to lower-risk patients, and to discuss
the potential advantages and challenges that this procedure will face in
this subset of patients.
2. Procedural risk assessment
Whichvariables are considered todefine apatient at low-intermediate
operative risk?Amultitude of relevant clinical and anatomical factorsmay
influence operative complexity, complicating precise risk assessment inmbrogio
r the CC BY-NCAS patients. Both, in clinical practice and in RCTs, the risk scores used
to support an indication for TAVR have been inherited from cardiac sur-
gery. All of the widely-used risk scores (STS-PROM, logistic EuroSCORE,
EuroSCORE II) have important limitations in predicting operative mor-
tality [6–7]. In the absence of a completely reliable risk model, the
STS-PROM has mostly been applied, in clinical practice and clinical
trials, for individual risk assessment. Historically, operative risk was
classified as high (STS-PROM N8%), intermediate (STS-PROM of 4–8%),
and low (STS-PROM b4%). However, while a surgical risk score accu-
rately predicts SAVR outcomes [8–9], it overestimates TAVR mortality
because of many confounders (i.e. general anaesthesia is not needed
for TAVR, and most variables present in the surgical scores such
as chronic pulmonary disease and renal insufficiency, have a lesser in-
fluence on TAVR outcomes). Furthermore, important additional factors
such as active malignancy, frailty, porcelain aorta, chest wall radiation,
liver cirrhosis, or neurological impairment, were not comprehensively
integrated in these risk models. Accordingly, the guidelines acknowledge
the imperfect nature of risk scores, and recommend that the decision to
perform TAVR should be made on the basis of multidisciplinary Heart
Team evaluation after a thoughtful clinical evaluation and the participa-
tion of patients and their families in the decision [1].3. Current evidence from randomized trials and large registries
3.1. Randomized studies
Three RCTs and multiple international prospective registries have
broadened the indications for TAVR to lower-risk patients.-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The NOTION (Nordic Aortic Valve Intervention) trial randomized
280 AS patients aged N70 years (and no significant coronary artery
disease) to TAVR (n = 145) with a first generation self-expanding
THV (Medtronic CoreValve) or SAVR (n = 135) at three Scandinavian
centres. Mean STS-PROM was 2.9 ± 1.6% in TAVR and 3.1 ± 1.7% in
SAVR patients. The access route was trans-femoral (TF) in 96.5% of
TAVR procedures [10].
Although the number of recruiting centres was relatively low and
the sample size small, this study provided important information on
selected low risk patients undergoing aortic valve replacement.
In the intention-to-treat population, no significant difference in the
primary endpoint (composite rate of death from any cause, stroke, or
myocardial infarction at 1 year) was found (13.1% vs. 16.3%; p = 0.43
for superiority). Even after stratifying patients into low- and
intermediate-risk (i.e. STS b4% vs. ≥4%) there was no statistically signifi-
cant difference in the composite end-point between the groups. TAVR pa-
tients suffered higher rates of permanent pacemaker (pPM) implantation
and para-valvular leak (PVL), had a worse NYHA functional class, but less
life-threatening bleeding, cardiogenic shock, new-onset atrial fibrillation,
and acute kidney injury (AKI) [10]. Recent 5-year data confirmed non-
inferiority of TAVR vs. SAVR regarding the composite end-point (TAVR
39.2% vs. SAVR 35.8%; p = 0.78) and the 5-year all-cause mortality of
27.7%was the lowest 5-year rate ever reported in a TAVR population [11].
3.1.2. PARTNER 2A
The Placement of Aortic Transcatheter Valves (PARTNER) was an
international trial involving 2032 intermediate-risk patients (mean
age 81.5 years, mean STS-PROM score 5.8%), who were randomized
either to TAVR with a second generation balloon-expandable (BE)
THV (SAPIEN XT system, Edwards Lifesciences, Irvine, CA) or to SAVR
[12]. TAVR in selected patients (subjects with concomitant severe coro-
nary artery disease such as unprotected left main or syntax score N32,
uni or bicuspid aortic valve, prior balloon aortic valvuloplasty, severe
left ventricular dysfunction with left ventricular ejection fraction b20%,
severe chronic kidney disease, were excluded) resulted non-inferior to
SAVR with respect to the primary end-point (all-cause death or
disabling stroke) at 2 years (19.3% in the TAVR group vs. 21.1% in the
SAVR group; p = 0.25). Of note, the percentage of patients undergoing
CABG in addition to SAVR was numerically higher compared to that
underwent PCI in addition to TAVR (14.5% vs. 3.9%). Importantly, a sub-
group analysis demonstrated superiority for the TF TAVR cohort com-
pared to SAVR (16.3 vs. 20%, p = 0.04). Similar to the NOTION trial,
TAVR resulted in lower rates of AKI, severe bleeding and new-onset atrial
fibrillation, but was associated with higher rates of major vascular com-
plications and significant PVL. Interestingly, rates of pPM implantations
were not significantly different in both groups with a faster recovery
and shorter hospitalization (in-hospital: 6 vs. 9 days, ICU: 2 vs. 4 days,
p b 0.001) were observed after TAVR.
3.1.3. SURTAVI
In the Surgical Replacement and Transcatheter Aortic Valve Implanta-
tion (SURTAVI) trial [13], a total of 1746 intermediate-risk patients (mean
age 79.8 years, mean STS score 4.5%) were randomized (recruitment
period of almost 4 years) to TAVR with the use of a self-expandable
(SE) prosthesis (CoreValve or Evolut R, Medtronic, Santa Rosa, CA) or
SAVR. Theprimary endpoint (a composite of all-cause death anddisabling
stroke at 2 years) was similar in both treatment arms (12.6% [TAVR] vs.
14% [SAVR], posterior probability of non-inferiority N0.999). Again, higher
rates of AKI, new onset atrial fibrillation, and transfusion requirements
were observed after SAVR while hemodynamic measures were in favor
of TAVR (trans-prosthetic gradients, effective orifice area), the incidence
of PVL and the need for pPM implantation were lower after SAVR.
Furthermore, a sub-analysis of this randomized study explored the
outcomes of TAVR vs. SAVR in patients with a STS-PROM score below
3% demonstrating a significantly lower rate of all-cause mortality ordisabling stroke in TAVR vs. SAVR at 1-year follow-up (1.5% vs.
6.5% p = 0.04) [14].
These results are confirmed by different meta-analysis of RCTs com-
paring TAVR vs. SAVR in low to intermediate risk patients that consis-
tently report no significant difference in mortality between the
groups, increased risks of pPM implantation, major vascular complica-
tions and moderate-to-severe PVL associated with TAVR, though
lower incidence of atrial fibrillation, severe bleeding, AKI and early
stroke [15–19].
Although the data coming from PARTNER 2A, SURTAVI and meta-
analysis of RCTs are consistent, longer-term follow-up (N2 years) are
needed to better understand the performance of a THV vs. a surgical
prosthesis over a long time period in lower risk patients.
3.1.4. PARTNER 3
The PARTNER 3 trial was a multicenter, RCT in which 1000 patients
(mean age 73.5 years) were randomized to TAVR with TF placement of
a third-generation BE THV (Sapien 3, Edwards Lifesciences, Irvine, CA;
which has a lower sheath profile [14–16 vs. 16–18 French], a steerable
commander delivery system and an outer sealing polyethylene
terephthalate fabric skirt) vs. a standard SAVR in patients with severe
AS and a low surgical risk (mean STS-PROM score 1.9%). The Kaplan–
Meier estimate of the rate of the primary composite end point (death,
stroke or re-hospitalization) at 1-year was significantly lower in the
TAVR group than in the SAVR group (8.5% vs. 15.1%; absolute difference,
−6.6 percentage points; 95% confidence interval [CI], −10.8 to
−2.5; p b 0.001 for non-inferiority; hazard ratio, 0.54; 95% CI,
0.37 to 0.79; p = 0.001 for superiority). The requirements for both
non-inferiority and superiority were met in favor of the percutaneous
procedure. At 30 days, TAVR resulted in a lower rate of stroke than
SAVR (p = 0.02), in lower rates of death or stroke (p = 0.01) and
new-onset atrial fibrillation (p b 0.001). TAVR also resulted in a shorter
index hospitalization than SAVR (p b 0.001). There were no significant
between-group differences in major vascular complications, pPM inser-
tions, ormoderate/severe PVL [20]. Although this trial has several limita-
tions, such as unblinded adjudication of the end-points (which could
have resulted in bias in outcome assessment), selected population (ex-
cluded patients with poor TF access, bicuspid aortic valves or other ana-
tomical or clinical factors that increased the risk of complications
associated with either TAVR or SAVR) and limited follow-up (actually
1-year), the findings reported suggest that the value of TAVR (performed
using a BE THV) as comparedwith SAVRmay be independent of risk pro-
files in patients with severe symptomatic AS.
3.1.5. Evolut TAVR in low risk patients
In this RCT a total of 1468 patients with severe symptomatic AS
underwent randomization to TAVR using a SE supra-annular THV
(CoreValve or Evolut R or Evolut Pro) or SAVR. The patients' mean age
was 74 years while mean STS-PROM score was 1.9%. The 24-month
estimated incidence of death or disabling stroke (primary end-point)
was 5.3% in the TAVR vs. 6.7% in the SAVR group demonstrating non-
inferiority of the percutaneous vs. the surgical procedure (difference,
−1.4 percentage points; 95% Bayesian credible interval for difference,
−4.9 to 2.1; posterior probability of non-inferiority N0.999). The pre-
specified criterion for superiority was not met. At 30 days, patients
who had undergone TAVR, as compared with SAVR, had a lower inci-
dence of disabling stroke (0.5% vs. 1.7%), bleeding complications (2.4%
vs. 7.5%), AKI (0.9% vs. 2.8%), and atrial fibrillation (7.7% vs. 35.4%) and
a higher incidence of moderate or severe aortic regurgitation (3.5% vs.
0.5%) and pPM implantation (17.4% vs. 6.1%) [21]. The most important
limitations of this study are the incomplete 24-month follow-up of the
entire cohort and the unblinded end-point adjudication for all end-
points, which may have resulted in bias in end-point assessment.
Furthermore, the latest-generation Evolut PRO THV was used in only
22.3% of the patients who received TAVR and this may have influenced
the higher incidence of moderate or severe aortic regurgitation in the
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coming from the PARTNER 3 RCT open to another less invasive therapeu-
tic option for the treatment of patients with tricuspid, stenotic aortic
valve.
3.1.6. Comparison analyses (not randomized)
A pre-specified propensity match analysis comparing the 1-year
clinical outcomes of 963 intermediate-risk patients included in the
SAPIEN 3 observational study (S3i) vs. 747 patients of the PARTNER 2A
surgical cohort (mean age 81.9 years, mean STS-PROM score 5.2%)
showed that TF TAVR was superior to SAVR for the composite endpoint
of mortality, stroke, and moderate/severe PVL. As opposed to PARTNER
2A, TAVR patients involved in this analysis received the new generation
SAPIEN 3 THV. Probably due to the lower sheath profile of this new
generation BE THV system the incidence of 30-daymajor vascular com-
plications was similar between the TAVR vs. the SAVR group (6.1% vs.
5.4%) [22].
The German Aortic Valve Registry (GARY) recently reported real-
world data comparing 1-year clinical outcomes of 7613 patients at
intermediate surgical risk (STS-PROM score 4%–8%) underwent isolated
TAVR (n= 6469) vs. SAVR. Patients treated by TAVR were significantly
older and had higher risk scores. Unadjusted in-hospital mortality rates
were equal for TAVR and SAVR (3.6% vs. 3.6%, p = 0.9), whereas un-
adjusted 1-year mortality was significantly higher in patients after
TAVR (17.5% vs. 10.8%, p b 0.001). After propensity score matching,
the difference in 1-year mortality between patients with TAVR (per-
formed through a trans-vascular access) and SAVR was no longer sig-
nificant (17.1% versus 15.7%, p = 0.59) [23]. In accordance with the
results from RCTs, this large registry analysis suggests that both TAVR
(performed through a trans-vascular access) and SAVR are reasonable
treatment options in a real-world population with AS and intermediate
surgical risk.
The Low Risk TAVR (Feasibility of Transcatheter Aortic Valve Replace-
ment in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis)
trial is a prospective, single-arm multicenter trial involving 200 low
risk patients (STS-PROM score below 3% and absence of comorbidity
that would increase surgical risk, including, but not limited to frailty,
porcelain aorta, severe pulmonary hypertension, and advanced liver
disease) underwent TAVR (most performed under moderate sedation
with a BE THV) compared vs. 719 patients who underwent isolated
SAVR in the same participating centres.
At 30 days, there were zero all-cause mortality and in-hospital
stroke in the TAVR group versus 1.7% and 0.6% in the SAVR group.
Permanent PM rates were similar between TAVR and SAVR (5.0% vs.
4.5%) while the rates of new-onset atrial fibrillation (3.0%) and length
of stay (2.0 ± 1.1 days) were low in the TAVR group. Of note, 14% of
TAVR patients had evidence of subclinical leaflet thrombosis at
30 days. This data demonstrate that TAVR is safe in low-risk AS patientsTable 1
Longest-available results from main studies comparing TAVR vs. SAVR in low-intermediate risk
Study name Time to
end-point
Mean overall
age (years)
Mean overall
STS-PROM (%)
All-cause
mortality (%)
Di
st
TAVR SAVR TA
NOTION 2 years 79.1 ± 4.8 2.9 ± 1.6 8.0 9.8 3
PARTNER 2 2 years 81.6 ± 6.7 5.8 ± 2.0 16.7 18 6
SURTAVI 2 years 79.8 ± 6.2 4.5 ± 1.5 11.4 11.6 2
SURTAVI
Low-risk
1 year 75.2 ± 6.0 2.4 ± 0.6 1.5 5.7
LRT 30-days 71.8 ± 7.2 1.7 ± 0.5 0 1.7
GARY
Low-risk
1 year 70.84 ± 10.88 2.3 ± 0.8 10 8.8 N
PARTNER 3 1 year 73.4 ± 5.9 1.9 ± 0.7 1.0 2.5 1
Evolut Low Risk TAVR 2 years 73.9 ± 5.9 1.9 ± 0.7 4.5 4.5 1
TAVR: transcatheter aortic valve replacement; SAVR: surgical aortic valve replacement; PM: pa
*: 30-day results; **: in-hospital results; NA: not available; °°: at 1-year follow-up.even if more studies are needed to better understandmechanisms, pre-
dictors and long-term prognostic implications of subclinical THV leaflet
thrombosis [24].
Low-risk patients (STS-PROM score b 4) underwent isolated TAVR
(n = 6062) or SAVR (n = 14,867) enrolled in the German Aortic
Valve Registry (GARY) [25] were compared by a weighted propensity
score model in order to assess in-hospital, 30-day, and 1-year mortality
between groups. TAVR patients showed a significantly higher in-
hospital (TAVR vs. SAVR: 98.5% vs. 97.3%; p = 0.003) and 30-day
(TAVR vs. SAVR: 98.1% vs. 97.1%; p = 0.014) survival than SAVR
patients. At 1-year, survival rates did not differ significantly (TAVR vs.
SAVR: 90.0% vs. 91.2%; p 0.158) (Tables 1 and 2).3.1.7. Minimally invasive surgical aortic valve replacement vs. TAVR
In recent years, minimally invasive (through a right antero-lateral
mini-thoracotomy or mini-sternotomy) SAVR has been increasingly
adopted with the goal to reduce the invasiveness of the surgical proce-
dure (reducing the intra-operative trauma and bleeding and accelerating
the post-operative recovery) but to offer the same quality, safety and
results as the standard conventional procedure.
Data coming from a meta-analysis of propensity match studies
demonstrated a benefit of this approach over the standard one, in
terms of a lower incidence of cardiac output syndrome and atrial fibril-
lation at the price of a longer aortic cross-clamp and cardiopulmonary
bypass times [26].
Theoretically, the mini-invasive approach could be an appealing
option (compared to conventional SAVR) for high risk AS patient re-
quiring valve replacement. Data coming from a single centre propensity
match analysis comparing SAVR using a sutureless bioprosthetic valve
(n = 37) vs. a BE first generation THV (n = 37) in high risk patients
(median logistic Euroscore I: 14%) of whom 51.6% treated through the
TF route, reported a not significant in-hospital mortality (TAVR 8.1%
vs. SAVR 0%, p = 0.2) and stroke (TAVR 5.4% vs. SAVR 0%, p = 0.3)
rates between the groups whereas mild-to-moderate PVL occurrence
was significantly higher in the TAVR group [27].
Furthermore, a recent meta-analysis of six propensity score
matching studies comparing sutureless SAVR vs. TAVR in high or inter-
mediate risk patients reported lower 30-day, 1- and 2-year mortality in
the SAVR group as well as lower incidences of post-operative stroke,
moderate-to-severe PVL and major vascular complications whereas
the incidence of bleedings requiring transfusions was higher in the
SAVR compared to TAVR group [28]. Although of interest, these data
deserve a careful interpretation due to the relatively low number of pa-
tients not enrolled in RCTs. Trials aiming to compare TF TAVR vs. SAVR
through a mini-invasive approach using a sutureless valve are required
to better understand the potential benefit of the less invasive surgical
strategy in the management of high-to-intermediate risk patients.patients.
sabling
roke (%)
PM
implantation
(%)
Moderate/severe
PVL (%)
Major vascular
complications
(%)
New onset
atrial
fibrillation (%)
VR SAVR TAVR SAVR TAVR SAVR TAVR SAVR TAVR SAVR
.6 5.4 41.3 4.2 15.4 0.9 5.6 1.5 22.7 60
.2 6.4 11.8 10.3 5.5 0.6 7.9 5.0 11.3 27.3
.6 4.5 25.9* 6.6* 4.9 0 6.0* 1.1* 12.9 43.4
0 1.7 24.6 3.4 3.6 0 3.1 0 15.4 47.3
0 0.6 5** 4.5** NA NA NA NA 3 4.8
A NA NA NA NA NA NA NA NA NA
.2 3.1 7.3 5.4 0.6 0.5 2.8 1.5 7.0 40.9
.1 3.5 19.4°° 6.7°° 3.5°° 0.5°° 3.8°° 3.5°° 9.8°° 38.3°°
cemaker; PVL: paravalvular leak; LRT: low risk TAVR Trial.
Table 2
Currently ongoing randomized trials comparing TAVR vs. SAVR in low-risk and in specific sub-set of patients with aortic stenosis.
NOTION 2 DEDICATE Bicuspid low risk TAVR Unload Early TAVR
Active since 2016 2017 Not recruiting 2016 2017
Estimated completion date 2024 2024 NA 2022 2031
Risk profile/subset STS-PROM b 3% and
Age b 75 years
STS-PROM
2–6%
Predictive operative
mortality risk b 3%
Bicuspid aortic valves
LVEF b 50%
Moderate AS
Asymptomatic severe AS
Sample size (patients, n=) 992 1600 150 600 1109
THV used Each CE marked Each CE marked Evolut Pro or Evolut R Sapien 3 Sapien 3
Route for TAVR TF only TF/TA/Tax/TAo TF/TAx TF TF
Primary end-point All-cause mortality,
myocardial infarction
or stroke
Overall survival All-cause mortality or
disabling stroke
All-cause mortality
Disabling stroke
Hospitalizations related to HF
Change in KCCQ
All-cause death, all stroke,
and unplanned cardiovascular
hospitalization
Design Non-inferiority RCT Non-inferiority RCT Non-inferiority RCT Superiority vs. medical therapy
Time-to-primary end-point 1-year 5-years 30-days 1-year 2-years
Maximum follow-up interval 1 year 5 years 10 years 2 years 10 years
Reference ClinicalTrial.gov NCT02825134 NCT03112980 NCT03635424 NCT02661451 NCT03042104
THV: transcatheter heart valve; RCT: randomized controlled trial; TF: transfemoral; TAx: transaxillary/transsubclavian; TA: transapical; Tao: transaortic; NA: not available.
TAVR: trans-catheter aortic valve replacement; LVEF: left ventricular ejection fraction; AS: aortic stenosis; HF: heart failure; KCCQ: Change in Kansas City Cardiomyopathy Questionnaire.
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Over the past decade, THV technology has significantly improved.
New THV devices with lower-profile delivery systems have increased
the proportion of patients who can be treated by the TF route and
have significantly reduced vascular complications [29]. Newer genera-
tion THV also have an additional sealing skirt, which reduces the risk
of PVL [30], and are often repositionable, which can result in higher
implants thereby reducing the risk of conduction disorders [31]. As
TAVR moves into younger AS populations, additional challenges need
to be addressed.4.1. Stenotic bicuspid aortic valves
As TAVR is performed in younger patients, the prevalence of bicuspid
ASwill considerably increasewith anestimate of 30–50% in thosepatients
aged 75 years or less [32]. Importantly, patients with bicuspid AS have
typically been excluded from the large RCTs. Therefore, we do not have
definitive data on how THVs perform against SAVR in the presence of
bicuspid valves. Therefore SAVR is actually considered the gold-standard
treatment for bicuspid AS in case of acceptable surgical risk.
An important issue when considering TAVR in bicuspid AS is the
assessments of these patients' anatomy (i.e. frequent aortic root aneu-
rysm and low coronary take-off). Appropriate valve sizing (probably
best at supra-annular or intra-leaflet level vs. the traditional annular
level [33]) and the modification of the implantation technique, with
specific attention to valve deployment and positioning (higher risk of
aortic injury because of associated aortopathy even in absence of dilata-
tion) are fundamentals according to a careful pre-procedural CT-scan
evaluation. Percutaneous treatment of bicuspid AS has been associated
with increased procedural risk (more frequent occurrence of aortic root
injury) and suboptimal short-term result (higher rates of PVL and pPM
implantation). As a large proportion of the younger AS patients has a
bicuspid valve, data on THV durability and long-term outcomes in this
specific cohort will be of paramount importance. Given the anatomical
features of a stenotic bicuspid aortic valve, THV implanted may not fully
expand or not become fully circular with asymmetric leaflets as a result.
Although this should not necessarily lead to immediate structural
valve deterioration (SVD), it has recently been reported that asymmetri-
cal leaflet expansion may be associated with an increased risk of sub-
clinical leaflet thrombosis [34]. Even if recent data coming from studies
of TAVR in bicuspid vs. tricuspid valves demonstrated a similar prognosis
[35–36], the design of specific THV devices to treat bicuspid anatomy
will become crucial to reduce the risk of PVL and pPM requirement in
younger patients.4.2. Permanent pacemaker implantation
Conduction disturbances requiring pPM implantation occur more
frequently after TAVR vs. SAVR [37]. Factors independent from surgical
risk such as THV design and anatomical aspects (aortic valve and left
ventricular outflow tract) mostly influence pPM implantation rates
which are similar between high and lower-risk patients (particularly
when a SE THV is implanted). As for mild PVL, it is unknown how fre-
quently pPM implantation and ventricular asynchrony will negatively
impact mortality or physical performance on long-term follow-up in
younger patients. On the other hand, it is clear that young patients are
exposed to the risk of pPM-related complications (i.e. lead infection,
endocarditis and for secondary tricuspid regurgitation) for a longer
period of time.
Also for this reason, the design of newer generation THV should take
into account this important point which could be very important to
favor a broadened use of TAVR in young patients.4.3. THV durability
Extension of TAVR to younger AS patients with longer life-expectancy
(N15–20 years) is actually limited because very little is known on long-
term (≥10 years) THV durability. A recently published consensus docu-
ment by EAPCI/ESC/EACTS standardized the definitions of SVD and
bioprosthetic valve failure (BVF) to assess long-term durability of trans-
catheter and surgical aortic bioprostheses [38]. SVD includes irreversible
intrinsic changes of the valve (i.e. calcification, flail, leaflet tear, pannus
deposition, orfibrotic leaflet) leading to degeneration and/or dysfunction,
potentially resulting in stenosis or regurgitation. The precise mechanism
of SVD are not known but likely include tissue disruption or thickening
over time because of mechanical stress in conjunction with abnormal
flow shear stress at the surface of valve leaflets, collagen fiber disruption,
and tissue calcification [39].
The term BVF integrates severe SVD (the etiology) with its clinical
consequences and is recommended to be used as the main outcome of
interest in studies assessing the long-term performance of TAVR and
SAVR. Importantly, BVF may occur in the setting of SVD but also as the
consequence of pathophysiological processes unrelated to SVD, such as
thrombosis, endocarditis or nonstructural valve dysfunction. In particular,
a broad spectrum of THV thrombosis presentation has been described,
from incidental findings to severe obstructive valve thrombosis with
clinical heart failure, occurring at variable time after TAVR [40–41].
The diagnostic criteria include a hemodynamic deterioration
(i.e., increase of mean transprosthetic gradient or significant new/
worsening intraprosthetic regurgitation), increased thickness or reduced
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reported a higher rate of reduced leaflet motion in TAVR patients than
surgically implanted aortic valve patients (13% versus 4% respectively;
p = 0.001) [42]. Regression of reduced leaflet motion or hypo-
attenuated leaflet thickening has been reported both after introduction
of anticoagulation or without any adjustment of the antithrombotic
regimen [34,43].
BVF includes any of the following: (1) bioprosthetic valve dysfunc-
tion at autopsy, very likely related to the cause of death, or “valve-related
death”; (2) aortic valve re-intervention (i.e. valve-in-valve TAVR, PVL
closure or SAVR); and (3) severe hemodynamic SVD. Long-term
follow-up (7 years) data from a real world German experience (in 300
high-risk and inoperable patients) using first generation THVs demon-
strated a 14.9% crude incidence of SVD (CoreValve 11.8% vs. Sapien
22.6%; p = 0.01) according to the EAPCI/ESC/EACTS definitions [44].
The same, have been also applied to the NOTION trial showing a lower
6-year rate of SVD in THV as compared to surgical aortic bio-prosthesis
(4.8% vs. 24%; p b 0.001) in low-risk patients, whereas there were no dif-
ferences in non-structural valve deterioration or endocarditis rates and
BVF between the groups [45]. Recently, the 5-year echocardiographic
follow-up on 459 high risk patients underwent TAVR demonstrated
good durability for both first generation types of THV with 2.5% severe
SVD in cumulative incidence function. In addition, the presence of severe
SVD was not associated with excess mortality [46]. Table 3 summarizes
long-term durability data after THV implantation.
However, obtaining longer-term (N5 years) follow-up results from
low-risk patients enrolled in RCTs is mandatory to provide definite
data on valve durability post-TAVR.
In this regard, the PARTNER 3 and Evolut R Low Risk RCTs will pro-
vide 10-year echocardiographic data assessing the incidence of SVD
and/or BVF in low-risk young patients that underwent TAVR.
4.4. TAVR-in-TAVR
Considering the probable extension of TAVR to younger patients
with longer life expectancy, treatment of SVD with a TAVR-in-TAVR
will probably increase. Recent data demonstrated that “redo TAVR” for
the treatment of THV failure is feasible, safe, and associated with
favorable haemodynamic results [47]. However, an open challenge
following TAVR-in-TAVR approach is coronary cannulation, which willTable 3
Main (comparative and single-arm) studies on transcatheter heart valve durability.
Author (year) Population Study type Patient's
surgical
risk
profile
Valve type
Toggweiler S et al. (2013) [54] TAVR only (n= 111) Registry High CE or ESV
Barbanti M et al. (2015) [55] TAVR only (n= 353) Registry High MCV
Mack MJ et al. (2015) [56] TAVR (n= 348) vs.
SAVR (n= 351)
Randomized High ESV vs. BSV
Dvir D et al. (2016) [57] TAVR only (n= 378) Registry High CE, ESV, SX
Gerckens U et al. (2017) [58] TAVR only (n= 860) Registry High MCV
Didier R et al. (2018) [59] TAVR only (n=
4201)
Registry High MCV, ESV,
SXT
Aldalati O et al. (2018) [59] TAVR (n= 269) vs.
SAVR (n= 174)
Registry High ESV, SXT, S3
Lotus vs. BS
Deusch MA et al. (2018) [44] TAVR only (n= 300) Registry High MCV vs. ES
Sondegaard L et al. (2019)
[45]
TAVR (n= 139) vs.
SAVR (n= 135)
Randomized Low MCV vs. BS
Blackman DL et al. (2019)
[60]
TAVR only (n= 241) Registry High ESV, SXT,
MCV
SVD: structural valve deterioration; TAVR: trans-catheter aortic valve replacement; CE: Cribier
SAVR: surgical aortic valve replacement; SXT: Sapien XT; NR: not reported; BSV: bio-prosthet
European Society of Cardiology; EACTS: European Association, Cardiac and Thoracic Surgery.be required more frequently as we treat young patients that may need
future coronary intervention. In this regard, special attention should
be payed to the choice of the first implanted THV type, in order to
minimize the potential obstruction in getting future access to the coro-
nary ostia given by the THV tissue/frames. In this regard the best THV
device to perform a TAVR-in-TAVR procedure is actually unknown.4.5. Stroke
Disabling stroke is a rare but potentially devastating complication
following TAVR or SAVR, particularly when occurring in younger pa-
tients [48]. Early reports showed a higher stroke rate associated with
TAVR when treating high-risk patients [3]. Successive improvements
in THV technology (i.e. reduction in the profile of delivery catheters
facilitating prosthesis positioning with less need for manipulation
within the native valve) and peri-procedural anaesthesiologic manage-
mentwith a larger use of conscious sedation (potentially associated to a
higher degree of intra-procedural haemodynamic stability) versus
general anaesthesia led to a reduction in early stroke rate [13,22,49].
Indeed, more recent data have demonstrated a lower incidence of
disabling stroke after TAVR vs. SAVR in low-risk patients [14,20,21,24].
Although rare, every effort should be made to avoid cerebral embolic
events in low-risk patients. In this regard, the use of embolic protection
devices (EPD) could be a helpful choice to prevent as well as the use of
neuroimaging guided endovascular approaches to solve, an acute brain
injury. Two randomized trials of TAVR protected by EPD reported no
benefits in terms of disabling stroke reduction but showed a signifi-
cantly lower frequency of clinically silent ischaemic cerebral lesions
detected by magnetic resonance imaging [50]. Importantly, the impact
of the silent ischaemic lesions on long-term neurological function is
unknown and this issue may be particularly relevant in case of TAVR
in lower-risk and younger patients.
Besides the risk of peri-procedural stroke, mid- and long-term
thrombo-embolism is increased by new-onset atrial fibrillation and
subclinical leaflet thrombosis. The first has consistently been more
frequently observed with SAVR while the second with TAVR
[12,13,42,51–53]. Interestingly, adjunctive pharmacotherapy after
TAVR is not standardized, even if anticoagulation with novel oral anti-
coagulants or warfarin (but not dual antiplatelet therapy) is effectiveFollow-up
(years)
SVD definition used SVD rate (%) SVD requiring
re-intervention
(%)
5 VARC 1 3.4 (moderate
degeneration)
0
5 VARC 1 1.4 (prosthesis failure)
2.8 (mild degeneration)
0.5% (VIV)
5 SVD requiring
SAVR
0 0
T 6–10 Mean gradient ≥
20 mmHg and/or
moderate central AR
50 NR
5 VARC 2 2.6 1.2
5 EAPCI/ESC/EACTS 2.5 (severe)
13.3 (moderate-severe)
NR
,
V
6.5 VARC 2 61 vs. 69 (p = NS) 0.4
V 7 EAPCI/ESC/EACTS 11.8 vs. 22.6 (p b 0.001) 1.1 (VIV)
V 6 EAPCI/ESC/EACTS 4.8 vs. 24 (p b 0.001) 2.2 vs.
0.7 (p= 0.6)
5–10 EAPCI/ESC/EACTS 9 NR
Edwards; ESV: Edwards Sapien Valve; MCV: Medtronic Core Valve; VIV: Valve-in-Valve;
ic surgical valve; EAPCI: European Association Percutaneous Coronary Intervention; ESC:
6 A. Ielasi et al. / IJC Heart & Vasculature 23 (2019) 100375in prevention and resolution of leaflet thrombosis and subsequent im-
paired leaflet motion.
4.6. Paravalvular leak
Technological advances in THVs design in association with improve-
ments in procedural planning contributed to thedecrease in the incidence
of moderate/severe PVL compared to early TAVR experiences [48]. In the
two recent low-risk RCTs the incidence of moderate-to-severe PVL was
relatively low ranging from 0.6% (using a new generation BE THV) to
3.5% (using a SE THV) [14,24]. Despite the low rates, TAVR remained infe-
rior to SAVRwith regard to this end-point even in low-risk patients when
treated with a SE THV. On the other hand, no differences were reported
between TAVR performed using a third generation BE THV vs. SAVR.
This aspect is relevant and should be taken into account during the deci-
sion making process in lower risk patients. Furthermore, factors that are
independent of age, surgical risk, and THV design, such as the presence
of annular and/or left ventricular outflow tract calcifications, eccentric
annulus and bicuspid AS, will continue to affect TAVR performance on
PVL [48].
5. A new heart team era?
Over recent years, increasing operator experience with TAVR has
meant that the procedure can now be planned in details and safely per-
formed under local anaesthesia, in a catheterization laboratory [61]
through a TF approach (N90% of TAVR cases) [62] by a minimalist
heart team (MHT) led by the local “cardiovascular physicians” that
have the higher endovascular experience and catheter skills (usually
interventional cardiologists). Data coming from a German Registry
show that absence of an on-site surgeon and surgical team from thepro-
cedure did not increase TAVRmortality ormorbidity [63]. There is also a
growing debate as towhether having the entire surgical teampresent in
TAVR is economically sustainable or necessary [64], particularly giving
the low rate of complications (i.e. annular rupture, coronary occlusion,
ventricular perforation) requiring surgical conversion [65]. Although
the (wrong) feeling of some cardiac surgeons is that they could be
excluded from TAVR procedure [62] it is widely believed that the role
of themodernHeart Team (composed by a cardiac surgeon, an interven-
tional cardiologist, a clinical cardiologist and a cardiovascular anaesthe-
siologist appropriately trained and proficient in the active management
of valvular heart disease) remains, today more than in the past, defi-
nitely central. With widening knowledge and expertise, the Heart
Team plays a key role in every decision-making process [66]. The ESC/
EACTS guidelines advocate centralized care, with a Class I recommenda-
tion that TAVR is performed in a heart valve centre with on-site surgery
andwithin an environment that provides comprehensive diagnostic and
treatment options (even choosing the best context where to perform
the procedure favoring HR over cath-lab in case of planned surgical
accesses or high-risk of intra-procedural complications due to specific
anatomical features). These heart valve centres, where a multidisci-
plinary team works together on a regular basis with established
communication structures, seem to be ideally placed to become
high-volume centres of excellence for the treatment of heart valve
disease. An interdisciplinary heart team approachwith sufficient training
is, in our opinion, the most important strategy to further improve clinical
outcomes after both, surgical or percutaneous AVR.
6. Conclusions
TAVR has become the first line therapy in patients who are not
suitable for SAVR and it is favored over SAVR in patients suitable for
TF access at increased/intermediate surgical risk (STS or EuroSCORE II
≥4% or logistic EuroSCORE I ≥ 10% or other risk factors not included in
these scores such as frailty, porcelain aorta, sequelae of chest radiation).Recent data coming from RCTs comparing TAVR vs. SAVR in low-risk
patients (STS-PROMb4%) demonstrated that TAVR performed by expe-
rienced operators through the TF route is associated with lower rates
of major clinical events compared to SAVR at 1- and 2-year follow-up,
respectively [20–21].
Whatever the decision (TAVR or SAVR), interventional cardiologists
and cardiac surgeons need to cooperate and work together (in a cath-
lab or in a HR deciding case-by-case in line with some specific pre-
assessed procedural aspects or theoretical risks) according to their skills
and needs with the aim to offer the best treatment for each patientwith
severe AS.
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